Skinvisible

Skinvisible Documents

Documents

100

Ticker

SKVI

ISIN

US8307032032

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Skinvisible SEC Filings

Type
Report
Date
10-QQuartalsbericht11/13/2025
10-QQuartalsbericht8/13/2025
10-QQuartalsbericht5/14/2025
10-KJahresbericht4/14/2025
NT 10-KNT 10-K-Formular3/31/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/23/2025
10-QQuartalsbericht11/19/2024
NT 10-QNT 10-Q-Formular11/14/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/3/2024
10-QQuartalsbericht8/15/2024
NT 10-QNT 10-Q-Formular8/14/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/4/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/29/2024
10-QQuartalsbericht5/15/2024
10-KJahresbericht4/16/2024
NT 10-KNT 10-K-Formular4/1/2024
NT 10-QNT 10-Q-Formular11/15/2023
10-QQuartalsbericht11/15/2023
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/25/2023
10-QQuartalsbericht8/14/2023
10-QQuartalsbericht5/10/2023
10-KJahresbericht3/30/2023
4Insidertransaktion2/2/2023
4Insidertransaktion2/2/2023
4Insidertransaktion2/2/2023
10-QQuartalsbericht11/14/2022
10-QQuartalsbericht8/10/2022
10-QQuartalsbericht5/16/2022
10-KJahresbericht3/31/2022
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/13/2022
10-QQuartalsbericht11/19/2021
NT 10-QNT 10-Q-Formular11/15/2021
10-QQuartalsbericht8/16/2021
10-QQuartalsbericht6/15/2021
NT 10-QNT 10-Q-Formular5/18/2021
10-KJahresbericht4/15/2021
NT 10-KNT 10-K-Formular3/29/2021
10-QQuartalsbericht11/23/2020
NT 10-QNT 10-Q-Formular11/16/2020
10-QQuartalsbericht8/19/2020
NT 10-QNT 10-Q-Formular8/14/2020
10-Q/A10-Q/A-Formular7/8/2020
10-QQuartalsbericht7/6/2020
NT 10-QNT 10-Q-Formular6/29/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/14/2020
10-KJahresbericht5/14/2020
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/14/2020
NT 10-KNT 10-K-Formular3/31/2020
10-QQuartalsbericht12/3/2019
NT 10-QNT 10-Q-Formular11/14/2019
4Insidertransaktion10/24/2019
4Insidertransaktion10/24/2019
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/22/2019
10-QQuartalsbericht8/16/2019
NT 10-QNT 10-Q-Formular8/14/2019
10-QQuartalsbericht5/24/2019
NT 10-QNT 10-Q-Formular5/15/2019
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/19/2019
10-KJahresbericht4/15/2019
4Insidertransaktion4/12/2019
4Insidertransaktion4/12/2019
NT 10-KNT 10-K-Formular4/1/2019
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/2/2019
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/27/2018
10-QQuartalsbericht11/14/2018
DEF 14ADEF 14A-Formular10/19/2018
UPLOADUPLOAD-Formular10/12/2018
PRER14APRER14A-Formular10/11/2018
PRER14APRER14A-Formular10/5/2018
UPLOADUPLOAD-Formular10/1/2018
PRER14APRER14A-Formular9/24/2018
UPLOADUPLOAD-Formular9/11/2018
PRER14APRER14A-Formular8/28/2018
10-QQuartalsbericht8/14/2018
UPLOADUPLOAD-Formular8/1/2018
PRER14APRER14A-Formular7/25/2018
UPLOADUPLOAD-Formular7/13/2018
PRER14APRER14A-Formular7/6/2018
UPLOADUPLOAD-Formular6/20/2018
PRER14APRER14A-Formular6/11/2018
UPLOADUPLOAD-Formular5/30/2018
10-QQuartalsbericht5/15/2018
PREM14APREM14A-Formular5/2/2018
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/29/2018
10-KJahresbericht3/23/2018
10-QQuartalsbericht11/14/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben10/20/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben9/25/2017
10-QQuartalsbericht8/21/2017
NT 10-QNT 10-Q-Formular8/14/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/8/2017
10-QQuartalsbericht5/15/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/20/2017
10-KJahresbericht4/17/2017
NT 10-KNT 10-K-Formular3/30/2017
4Insidertransaktion3/28/2017
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/23/2017
10-QQuartalsbericht11/17/2016
NT 10-QNT 10-Q-Formular11/14/2016
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/8/2016

Skinvisible Documents 2026

This page contains all official documents and SEC filings for Skinvisible stock (SKVI, ISIN: US8307032032). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Skinvisible's regulatory filings.

Skinvisible Stock analysis

Skinvisible Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc.